企业QQ
官方微信
苏州蚂蚁淘生物科技有限公司为innovative ResearchX品牌在华授权代理商，
公司不仅坚持提供传统标记的二抗（如酶标记，AMCA，FITC，罗丹明，Cy系列等），
而且始终与*的染料生产商合作，以最快的速度供应新型染料标记的二抗（如Alexa Fluor，DyLight 405）。
若您对innovativeX产品感兴趣，请致电 0512-67156496 了解详情
China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the “Group”) is a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. The Group was established in 1995, and was listed on the Main Board Market of the Stock Exchange of Hong Kong Limited (stock code: 867) on 28 September 2010. CMS has been included in the Morgan Stanley Capital International (MSCI) China Index as well as the Hang Seng Stock Connect Biotech 50 Index (HSSCB50), and is the object of transaction in both Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. The Group is also the largest shareholder of Tibet Rhodiola Pharmaceutical Holding Co. (stock code: 600211), a listed company of Shanghai Stock Exchange (A-share).
By capitalizing on its resources of global product development for more than two decades, as well as its market reputation, CMS has established the strategic cooperation with a number of leading pharmaceutical companies around the world and made equity investments in R&D companies from the UK, France, the US and Switzerland. The Group’s innovative pipeline includes the products with great market potential and competitive differentiation advantages at relatively high innovation level and with a wide range of therapeutic areas. CMS has become a trustworthy and highly recognized cooperation partner for world’s leading pharmaceutical and innovative R&D companies who are willing to enter China market.
With the benefits of its proven and successful experiences in drug commercialization for over two decades, the Group has created good sales records for a number of quality branded drugs and received the high recognition from dozens of world’s leading pharmaceutical companies. The Group concentrates on exploring the evidence-based medical evidence and differentiation competitive advantages of the drugs, and has established a professional, compliant and efficient academic promotion system. Combined with its timely, refined, transparent and efficient internal management system, the Group has become one of the most efficient pharmaceutical companies in the field of marketing and promotion of prescription drugs.
Along with the value chain of pharmaceutical industry, CMS has paid special attention to two core elements, product competence and promotion capability. Over the past decade (from 2010 to 2019), the Group has achieved the rapid growth with a turnover compound annual growth rate (“CAGR”) of 25.6%, and a net profit CAGR of 28.4%. The Group’s return on equity has maintained over 20% for more than a decade. By converging the R&D forces and innovative resources around the world, CMS will work diligently to fulfill its mission to continually introduce more affordable innovative products with differentiation competitive advantages to benefit more Chinese patients and their families.
蚂蚁淘主营海外试剂抗体，进口科研仪器，海外试剂耗材等所有行业相关用品进口。蚂蚁淘全球直采，正品保障，为科研献力！如需商业合作，请联系cooperation@ebiomall.com 。
当前位置：关于CMS > 重大事件 2020年 获得中华人民共和国国家药品监督管理局颁发的环孢素滴眼液0.09％用于治疗干眼症的临床试验通知 PLENITY的收购的产品的权利®，体重管理设备，在大中国，新加坡和阿联酋 纳入恒生沪港通生物技术50指数 获得大分子中国新分子实体Desidustat的产品权 2019年 从中华人民共和国国家药品监督管理局获得地西p鼻喷雾剂的临床试验通知，并需要在中国受试者中进行比较药代动力学研究 获得7种创新产品的产品权，包括环孢素滴眼液0.09％，Tildrakizumab（生物制剂）和紫杉醇注射浓缩液在大中华地区的悬浮剂 在大中华地区或中国大陆获得11种仿制药（包括复杂仿制药）的产品权利 2018年 对包括Neurelis，Acticor Biotech，Blueberry Therapeutics和VAXIMM在内的4家海外创新研发公司进行了股权投资；以及在大中华区和（或）其他指定地点获得的4种创新产品的资产或权利，包括地西p鼻喷雾剂，ACT017（抗血小板人源化单克隆抗体），BB2603（特比萘芬纳米喷雾剂）和VXM01（口服T细胞免疫激动剂）亚洲国家 在大中华地区获得2种创新产品的产品权，包括新型铅小分子化合物CF101和CF102 在大中华地区收购PoNS™（便携式神经调节刺激器）的资产 2017年 对海外研发公司Destiny Pharma进行了股权投资；并在中国和其他亚洲国家（日本除外）收购了XF-73和其他抗菌产品组合的资产 增资完成后，继续成为西藏药业的第一大股东，持有36.83％的股权 2016年 取得Plendil在中国大陆商业化的独家权利 2015年 收购西丽药业并获得丹神通在中国大陆的独家销售和营销权 在中国大陆，大中华区和其他指定国家或地区的Hirudoid的资产收购 2014年 纳入摩根士丹利资本国际（MSCI）中国指数 成为西藏药业的第一大股东，共拥有26.61％的股权 Augentropfen施图尔恩单滴眼液和MOVICOL的收购资产®在中国（包括香港和澳门），溴隐亭®在中国（包括香港和台湾），以及兰美抒®在中国大陆 2011年 收购天津普瑞德医药贸易发展有限公司（2011年10月24日正式更名为天津康哲医药技术开发有限公司）100％的股权。 2010 在香港交易所主板上市（股票代码：867） 获得在中国大陆推广和销售Bioflor的专有权 2008年 获得在中国大陆推广和销售新活素，Cystistat和Salofalk的专有权 2006年 取得在中国大陆地区推广和销售Augentropfen Stulln Mono眼药水和GanFuLe的专有权 2002年 获得在中国大陆推广和销售Deanxit和Ursofalk的专有权 1998年 关联公司获得在中国大陆推广和销售Ursofalk的专有权 1997年 关联公司获得在中国大陆推广和销售Deanxit的专有权 1995年 CMS成立